Feedback
Settings

Settings

Goto Application

1. WO2021001651 - HDAC INHIBITORS FOR USE IN THE THERAPY OF BILIARY TRACT CANCERS

Submit observation
PermaLink
Publication Number WO/2021/001651
Publication Date 07.01.2021
International Application No. PCT/GB2020/051583
International Filing Date 01.07.2020
IPC
A61K 31/506 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • KARUS THERAPEUTICS LTD. [GB]/[GB]
Inventors
  • MCHALE, Duncan
  • YAVARI, Arash
Agents
  • STEVENS, Fiona
Priority Data
1909466.301.07.2019GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HDAC INHIBITORS FOR USE IN THE THERAPY OF BILIARY TRACT CANCERS
(FR) INHIBITEURS DE HDAC POUR UNE UTILISATION DANS LE TRAITEMENT DE CANCERS DU TRACTUS BILIAIRE
front page image
Abstract
(EN)
The present invention relates to a compound of formula (I), or its pharmaceutically acceptable salt. The compound, or its pharmaceutically acceptable salt, is useful as a HDAC inhibitor and therefore in therapy. In particular, the compound, or its pharmaceutically acceptable salt, has utility in the treatment of biliary tract cancer. (I)
(FR)
La présente invention concerne un composé de formule (I), ou son sel pharmaceutiquement acceptable. Le composé, ou son sel pharmaceutiquement acceptable, est utile en tant quiInhibiteur de HDAC et par conséquent en thérapie. En particulier, le composé, ou son sel pharmaceutiquement acceptable, a une utilité dans le traitement du cancer des voies biliaires. (I)
Latest bibliographic data on file with the International Bureau
# -